We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · October 01, 2020

Neoadjuvant Atezolizumab Plus Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy vs Placebo and Chemotherapy for Early-Stage Triple-Negative Breast Cancer

The Lancet


Additional Info

The Lancet
Neoadjuvant Atezolizumab in Combination With Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy Versus Placebo and Chemotherapy in Patients With Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Randomised, Double-Blind, Phase 3 Trial
Lancet 2020 Sep 18;[EPub Ahead of Print], EA Mittendorf, H Zhang, CH Barrios, S Saji, KH Jung, R Hegg, A Koehler, J Sohn, H Iwata, ML Telli, C Ferrario, K Punie, F Penault-Llorca, S Patel, AN Duc, M Liste-Hermoso, V Maiya, L Molinero, SY Chui, N Harbeck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading